Retrospective French real-world cohort of 155 women with early ER-low (1-9%), HER2-negative breast cancer given the KEYNOTE-522 pembrolizumab plus neoadjuvant chemotherapy regimen: 111 (71.9%) had a pathological complete response.
RCTn = 155
Cherifi et al. PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort